Use of live Saccharomyces cerevisiae cells as a biological response modifier in experimental infections.
A short-term oral administration of live Saccharomyces cerevisiae cells, strain Sillix Hansen DSM 1883, resulted in enhanced resistance of mice toward infections with K. pneumoniae. S. pneumoniae and S. pyogenes A produced by intranasal inoculation. Yeast pre-treatment also increased the efficacy of antibiotic therapy in bacterial infections and of antiviral drugs in viral infections. Yeast treatment of animals stimulated phagocytosis, activated the complement system and induced interferon which are likely to represent the main mechanisms of action whereby pretreatment of mice with live S. cerevisiae cells increases resistance to infection. It is concluded that preventive administration of live Saccharomyces cerevisiae cells should be used for increasing resistance to bacterial infections, in particular of the respiratory tract, or to viral infections, as well as an adjunct to antibiotic and antiviral drug therapy.
Bizzini
B
B
Laboratory of Toxin Immunochemistry, Pasteur Institute, Paris, France.
Fattal-German
M
M
D000276:Adjuvants, Immunologic; D000284:Administration, Oral; D000818:Animals; D000917:Antibody Formation; D001424:Bacterial Infections / Q000276:immunology / Q000628:therapy*; D003167:Complement Activation; D005260:Female; D007155:Immunologic Factors / Q000008:administration & dosage / Q000627:therapeutic use*; D051379:Mice; D009504:Neutrophils / Q000276:immunology; D012441:Saccharomyces cerevisiae / Q000276:immunology*; D014777:Virus Diseases / Q000276:immunology / Q000628:therapy
D000276:Adjuvants, Immunologic; D007155:Immunologic Factors